We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0GQU market cap is 1.03B. The company's latest EPS is SEK -0.1266 and P/E is -22.51.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 8.43M | 6.73M | 0 | 0 | 0 |
| Operating Income | -32.29M | -32.31M | -49.78M | -57.89M | -46.48M |
| Net Income | -34.13M | -32.25M | -49.83M | -58.37M | -45.8M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 66.95M | 32.16M | 56.8M | 51.01M | 44.05M |
| Total Liabilities | 13.17M | 10.04M | 10.13M | 16.49M | 13.38M |
| Total Equity | 53.78M | 22.11M | 46.67M | 34.51M | 30.67M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -35.81M | -32.22M | -46.17M | -54.85M | -45.74M |
| Investing | 275M | N/A | N/A | -245k | N/A |
| Financing | -205.06M | -1.25M | 73.09M | 43.76M | 40.16M |
| Market Cap | 1.03B |
| Price to Earnings Ratio | -22.51 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 28.47 |
| Price to Book Ratio | 33.62 |
| Dividend Yield | - |
| Shares Outstanding | 361.74M |
| Average Volume (1 week) | 1 |
| Average Volume (1 Month) | 1.91k |
| 52 Week Change | 0.00% |
| 52 Week High | 2.85 |
| 52 Week Low | 2.85 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Active Biotech Ab |
| Address |
scheelevagen 22 lund SE-223 63 |
| Website | https://www.activebiotech.com |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
